Please login to the form below

Not currently logged in
Email:
Password:

Novasep names Michel Spagnol CEO

Joins contract manufacturing firm from Shasun

Novasep Michel Spagnol Novasep has appointed Michel Spagnol as its new president and CEO, succeeding Patrick Glaser who returns to the US.

Spagnol joins French contract manufacturing firm Novasep from Shasun, where he was president and chief technology officer.

Prior to Shasun, Spagnol spent his career at Rhodia in Lyon, France and New Jersey, US, where he progressed first in technical R&D leadership roles and subsequently transitioned to business development as sales and marketing vice president of Rhodia Pharma Solutions.  

He joins Novasep as the company looks to expand through investments in its manufacturing capabilities in both France and China.

“His track record in delivering customer driven solutions, his international and scientific background coupled with his extensive management experience, longstanding knowledge and relationships in the pharmaceutical industry will be strong assets for the company,” said Roger-Marc Nicoud, founder and non-executive chairman of the board of Novasep.

9th July 2013

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
KVA Digital

KVA is an award winning full-service digital communications & brand experience agency. Our healthcare expertise blends creative ‘outside-the-box’ thinking with...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....